-
公开(公告)号：US11000531B2
公开(公告)日：2021-05-11
申请号：US16829661
申请日：2020-03-25
IPC分类号： A61K31/57 , A61K31/565 , A61K31/573 , C07J7/00 , A61K45/06 , A61K31/5513 , A61K47/36 , A61K47/69 , A61K47/32 , A61K47/10 , A61K9/00 , C08B37/16 , A61K47/38 , A61K9/107 , A61K31/718 , A61K31/721
摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
-
公开(公告)号：US20180071315A1
公开(公告)日：2018-03-15
申请号：US15700314
申请日：2017-09-11
IPC分类号： A61K31/573 , C07J7/00
CPC分类号： A61K31/573 , A61K9/0019 , A61K9/1075 , A61K31/5513 , A61K31/57 , A61K31/718 , A61K31/721 , A61K45/06 , A61K47/10 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/6951 , C07J7/009 , C08B37/0015 , A61K2300/00
摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
-
公开(公告)号：US20200179403A1
公开(公告)日：2020-06-11
申请号：US16705541
申请日：2019-12-06
摘要： Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.
-
公开(公告)号：US11266662B2
公开(公告)日：2022-03-08
申请号：US16705541
申请日：2019-12-06
摘要： Uses of ganaxolone in prophylaxis and treatment of postpartum depression are described. A dose of ganaxolone is administered to a female suffering from postpartum depression or at risk of developing postpartum depression in an amount and at a rate sufficient to alleviate at least one symptom of postpartum depression in the female.
-
公开(公告)号：US20200289530A1
公开(公告)日：2020-09-17
申请号：US16829661
申请日：2020-03-25
IPC分类号： A61K31/573 , C07J7/00 , A61K45/06 , A61K31/5513 , A61K47/36 , A61K47/69 , A61K47/32 , A61K47/10 , A61K9/00 , C08B37/16 , A61K47/38 , A61K31/57 , A61K9/107
摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
-
公开(公告)号：US10391105B2
公开(公告)日：2019-08-27
申请号：US15700314
申请日：2017-09-11
IPC分类号： A61K31/56 , A61K31/573 , C07J7/00 , A61K31/721 , A61K31/718
摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurossteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
-
公开(公告)号：US20220249515A1
公开(公告)日：2022-08-11
申请号：US17703331
申请日：2022-03-24
IPC分类号： A61K31/565 , A61K9/08 , A61K9/48 , A61P25/08 , A61K47/34 , A61K47/24 , A61K47/12 , A61K47/26 , A61K9/00
摘要： The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal. In certain preferred embodiments, the mammal is a human patient who has a CDKL5 genetic mutation. In certain preferred embodiments, the patient has a low endogenous level of a neurosteroid(s). In certain preferred embodiments, the pregnenolone neurosteroid is ganaxolone.
-
公开(公告)号：US20190167698A1
公开(公告)日：2019-06-06
申请号：US16150782
申请日：2018-10-03
IPC分类号： A61K31/573 , C07J7/00
摘要： The disclosure provides a method of treating a patient having postpartum depression, premenstrual dysphoric disorder, menopausal depression, or delirium tremens comprising administering an effective amount of an injectable neurosteroid formulation to the patient. In certain embodiments the injectable neurosteroid formulation is an injectable ganaxolone formulation. Two types of injectable neurosteroid formulations may be used in the disclosed methods. The first such formulation is an injectable formulation containing ganaxolone and sulfobutyl ether β-cyclodextrin in a 1:1 inclusion complex. The second such formulation is an injectable neurosteroid formulation comprising a neurosteroid, preferably ganaxolone, but which may be a neurosteroid selected from allopregnanolone, ganaxolone, alphaxalone, alphadolone, hydroxydione, minaxolone, pregnanolone, tetrahydrocorticosterone, and combinations of the foregoing; a surface stabilizer selected from hydroxyl ethyl starch, dextran, and povidone; and a surfactant.
-
公开(公告)号：US20190160078A1
公开(公告)日：2019-05-30
申请号：US16185677
申请日：2018-11-09
IPC分类号： A61K31/565 , A61K9/08 , A61K9/48 , A61K47/38 , A61K47/34 , A61K47/24 , A61K47/12 , A61K47/26 , A61P25/08
摘要： The disclosure provides a method of treating a mammal having a genetic epileptic disorder, comprising chronically administering a pharmaceutically acceptable pregnenolone neurosteroid to a mammal having a genetic epileptic disorder in an amount effective to reduce the seizure frequency in the mammal. In certain preferred embodiments, the mammal is a human patient who has a CDKL5 genetic mutation. In certain preferred embodiments, the patient has a low endogenous level of a neurosteroid(s). In certain preferred embodiments, the pregnenolone neurosteroid is ganaxolone.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
